Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Free cash flow
Vertex Pharmaceuticals Incorporated's free cash flow for fiscal 2025 was $3.2B, compared with −$978.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.8B. Over the past ten years it has ranged from −$978.0M (fiscal 2024) to $3.9B (fiscal 2022); the current reading is higher than 82% of that period. Vertex Pharmaceuticals Incorporated ranks 1st of 613 Biotechnology companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $3.2B | — |
| FY2024 | −$978.0M | — |
| FY2023 | $3.3B | (16.47%) |
| FY2022 | $3.9B | 62.97% |
| FY2021 | $2.4B | (19.55%) |
| FY2020 | $3.0B | 100.39% |
| FY2019 | $1.5B | 27.16% |
| FY2018 | $1.2B | 57.59% |
| FY2017 | $745.5M | 315.24% |
| FY2016 | $179.5M | — |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $1.0B | (21.74%) |
| Mar 2026 | $1.3B | 271.40% |
| Dec 2025 | $348.6M | (69.41%) |
| Sep 2025 | $1.1B | 22.88% |
| 42 more quarters | Free account |
Against its own ten years
Low −$978.0M
High $3.9B
Ten-year median
$1.5B
Current reading's percentile
82
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $3.8B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $3.6B |
| ARGX argenex SE compare | $1.4B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.3B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $819.9M |
| INSM Insmed, Inc. compare | −$807.7M |
| RVMD Revolution Medicines, Inc. compare | −$1.2B |
| MRNA Moderna, Inc. compare | −$1.2B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on VRTX
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement